In this article, we will be taking a look at the 15 Innovative Healthcare Stocks to Buy According to Analysts.Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs. As concerns about value grow, investors are moving their funds from the crowded AI industry to sectors with more enticing risk-reward profiles. The healthcare industry is one significant sector that has profited immensely from this shift.Since President Donald Tru ...

Profitability metrics were largely in line with expectations previously communicated. Lombardi said gross margin was 55.5% and adjusted diluted EPS was $1.14, consistent with guidance given on the company’s second-quarter call. Sacco said adjusted diluted EPS declined from $1.22 in the prior-year quarter due to lower sales, the timing of advertising and marketing spending, and higher G&A costs.Management characterized the consumer backdrop as challenging and dynamic, citing ongoing changes in where consumer ...

Core Insights - Haemonetics Corporation (HAE) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.31, reflecting a year-over-year increase of 10.1% and exceeding the Zacks Consensus Estimate by 3.1% [1][9] - The company's revenues decreased by 2.7% to $339 million, which still surpassed the Zacks Consensus Estimate by 1.4% [2][9] Revenue Breakdown - Plasma segment revenues reached $138.9 million, up 3.5% year over year, with organic growth of 2.8%, driven by strong demand for immunoglobulin [3] - Blood Center revenues fell 19.6% to $56.6 million, although organic growth was 2.8%, supported by international Plasma demand [4] - Hospital revenues slightly decreased by 0.3% to $143.5 million, with a 0.9% decline on an organic basis [4] Margin Performance - Gross profit increased by 4.6% to $202.4 million, with gross margin expanding by 418 basis points to 59.7% due to an 11.9% decline in the cost of sales [6] - Operating profit rose to $79 million, compared to $71.3 million in the prior year, with an operating margin increase of 287 basis points to 23.3% [7][9] Financial Position - At the end of the third quarter, Haemonetics had cash and cash equivalents of $363.4 million, up from $296.4 million at the end of the previous quarter [8] - Long-term debt remained stable at $920 million, and cumulative net cash flow from operating activities increased to $222.3 million from $65.2 million a year ago [8] Guidance - The company now expects fiscal 2026 GAAP revenues to decline by 1-3%, with organic revenue growth anticipated in the range of 0-2% compared to fiscal 2025 [10] - Adjusted EPS guidance for full-year 2026 is set between $4.90 and $5.00, up from the previous range of $4.80 to $5.00 [11] Overall Assessment - Haemonetics demonstrated better-than-expected results in the fiscal third quarter, with earnings and revenues surpassing estimates despite a year-over-year revenue decline [12] - The performance highlights the strength of the company's core businesses, particularly in Blood Management Technologies and Plasma, while targeted actions are planned to improve Interventional Technologies [12][13]

Core Insights - STERIS plc reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.53, reflecting a 9% increase year-over-year, matching the Zacks Consensus Estimate [2][9] - The company's GAAP EPS was $1.96, up 12% from $1.75 in the previous year [2] Revenue Performance - Total revenues from continuing operations reached $1.50 billion, marking a 9.5% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.1% [3][9] - Organic revenues at constant exchange rate (CER) rose by 8% year-over-year [3] - Revenue breakdown by segment: - Healthcare segment revenues increased by 9% to $1.10 billion, with service revenues up 11%, consumable revenues up 8%, and capital equipment revenues up 7% [4] - Applied Sterilization Technologies (AST) revenues improved by 11% to $286.6 million, driven by 9% growth in service revenues and a significant 103% increase in capital equipment revenues [5] - Life Sciences segment revenues rose by 7% to $145.8 million, with consumable revenues up 11% and capital equipment revenues up 7% [6] Margin Analysis - Gross profit for the quarter was $655.5 million, a 7.4% increase from the prior year, but gross margin contracted by 72 basis points to 43.8% due to a 10.6% rise in the cost of revenues [7] - Selling, general and administrative expenses rose by 5% to $352.3 million, while research and development expenses increased by 7.7% to $29.5 million [8] Financial Guidance - STERIS maintained its fiscal 2026 guidance, expecting revenue growth of approximately 8-9% and adjusted EPS in the range of $10.15-$10.30 [11] - The Zacks Consensus Estimate for revenues is $5.93 billion, implying an 8.6% growth from fiscal 2025 [11] Overall Assessment - The company ended the third quarter on a mixed note, with earnings meeting estimates and revenues exceeding expectations, while all business segments experienced growth [12] - Despite increased costs impacting gross margins, the expansion of operating margins is viewed positively for the stock [12]

Core Insights - Bio-Techne Corporation (TECH) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 46 cents, exceeding the Zacks Consensus Estimate by 8.2% and reflecting a year-over-year increase of 9.5% [1] - The company's net sales for the quarter were $295.9 million, showing a slight decline of 0.4% year over year, but surpassing the Zacks Consensus Estimate by 1.3% [2] - The operating profit for the quarter was $54.5 million, an increase from $47.4 million in the prior year, with the operating margin expanding by 244 basis points to 18.4% [6][8] Revenue Breakdown - In the Protein Sciences segment, Bio-Techne recorded revenues of $215.1 million, a 2% increase year over year, although it was down 1% on an organic basis [3] - The Diagnostics and Spatial Biology segment saw a revenue decrease of 4% year over year to $81.2 million, but it increased by 3% on an organic basis [4] Margin Analysis - Gross profit fell by 1.3% to $191.3 million, with the gross margin contracting by 63 basis points to 64.6% due to a 1.4% rise in the cost of sales [5] - Selling, general and administrative expenses decreased by 6.4% to $113.7 million, while research and development expenses totaled $23.1 million, down 7.6% year over year [5] Financial Position - At the end of the fiscal second quarter, Bio-Techne had cash and equivalents of $172.9 million, up from $145 million at the end of the previous quarter, while long-term debt obligations decreased to $260 million from $300 million [7] Overall Performance - Despite a quarterly revenue decline and gross margin contraction, there are signs of stabilization in the U.S. academic market, improving performance in biotech, ongoing growth in Asia, and continued strength among large pharmaceutical customers [10]

Core Thesis - Prestige Consumer Healthcare Inc. (PBH) is viewed as a compelling investment opportunity following its acquisition of Stampede Culinary Partners for $662.5 million, which is expected to enhance its EBITDA significantly [2][3]. Company Overview - PBH develops, manufactures, markets, distributes, and sells over-the-counter health and personal care products in North America, Australia, and internationally [2]. Acquisition Details - The acquisition of Stampede Culinary Partners is structured with $512.5 million in cash, $150 million in stock (approximately 5% dilution), and an additional $100 million earn-out over two fiscal years [2]. - This acquisition is projected to contribute approximately 15% to PBH's EBITDA, with initial mid-single-digit EPS accretion expected to rise to high-single-digit accretion after operational efficiencies are realized, effectively reducing the acquisition multiple to 7.5x [3]. Financial Performance - PBH's earnings run-rate has grown significantly since 2017, although the stock trades near mid-2017 levels. Current-year EPS valuation is around 21x, while next year's estimates reflect a 39% EPS growth, implying a multiple closer to 15x [4]. - The company has a dividend yield above 3% and is positioned for strong growth through strategic acquisitions and organic expansion [5]. Strategic Positioning - PBH's growth strategy has historically combined acquisitions and organic expansion, positioning it as a specialty food producer and distributor in Canada and the U.S. [3]. - Successful integration of Stampede and leveraging operational efficiencies could unlock significant shareholder value while expanding PBH's presence in North America's specialty food sector [5].

Core Insights - Neogen Corporation (NEOG) reported adjusted earnings per share (EPS) of 10 cents for Q2 fiscal 2026, exceeding the Zacks Consensus Estimate by 42.86%, but down from 11 cents in the same quarter last year [2] - Revenues for the quarter decreased by 2.8% year-over-year to $224.69 million, with core revenues increasing by 2.9%, surpassing the Zacks Consensus Estimate by 7.93% [3][10] Revenue Breakdown - The Food Safety segment generated revenues of $165.6 million, reflecting a 0.8% year-over-year increase, driven by 4.1% core revenue growth, despite a negative impact from divestitures and discontinued products [4] - The Animal Safety segment reported revenues of $59.1 million, down 11.8% year-over-year, with a slight core revenue increase of 0.1% and a significant negative impact from divestitures [5] Margin and Expense Analysis - Gross profit for Q2 declined by 5.9% year-over-year to $106.7 million, with a gross margin contraction of 153 basis points to 47.5% [6] - Sales and marketing expenses decreased by 9.1% to $42.3 million, while administrative expenses rose by 12.9% to $65 million, leading to an operating loss of $5.4 million compared to a profit of $3.9 million in the prior year [7] Cash Position and Liabilities - Neogen's cash and cash equivalents at the end of Q2 totaled $145.3 million, an increase from $138.9 million at the end of Q1 [8] - The company has total outstanding debt of $800 million and a committed borrowing capacity of $201.5 million [8] Fiscal 2026 Outlook - Neogen raised its fiscal 2026 revenue guidance to a range of $845 million to $855 million, up from the previous estimate of $820 million to $840 million, with adjusted EBITDA expected to be around $175 million [10][11] - The company noted encouraging early progress with a return to positive core growth across the enterprise [12] Segment Performance Highlights - Within the Food Safety segment, the strongest core revenue growth was observed in Indicator Testing and Culture Media, attributed to higher sales of sample collection products [13] - The Biosecurity product category in Animal Safety saw strong growth in insect control product sales [13]

Company Overview - Prestige Consumer Healthcare Inc. (NYSE:PBH) is a New York-based provider of over-the-counter (OTC) health and personal care products, incorporated in 1996, operating through two segments: North American OTC Healthcare and International OTC Healthcare [4] Investment Potential - Prestige Consumer Healthcare Inc. is considered one of the cheap healthcare stocks to buy heading into 2026, with a consensus 1-year median price target of $80, indicating an upside of nearly 32% [1] - Analysts remain bullish on the stock, maintaining a 'Buy' rating despite a recent price target adjustment from $100 to $88 by Canaccord [2] Financial Performance - In the second-quarter results announced on November 6, the company experienced a 6.1% decline in North American segment revenues, which was offset by a 2.5% rise in international segment revenues [3] - Management indicated that sales and earnings outperformed expectations due to specific factors, including Clear Eyes supply timing and retailer order timing, which may impact third-quarter results [2][3] Strategic Focus - The company remains focused on product innovation and e-commerce strategies as part of its growth initiatives [3]

Core Insights - Brandes Small Cap Value Fund reported a return of 11.16% for Q3 2025, underperforming its benchmark, the Russell 2000 Index, which gained 12.39%, and the Russell 2000 Value Index, which returned 12.60% [1] Company Highlights - Prestige Consumer Healthcare Inc. (NYSE:PBH) is a key holding in the Brandes Small Cap Value Fund, focusing on over-the-counter health and personal care products [2] - The stock of Prestige Consumer Healthcare Inc. experienced a one-month return of -0.94% and a significant decline of 28.26% over the past 52 weeks, closing at $59.94 per share with a market capitalization of $2.95 billion on December 09, 2025 [2] - The small-cap investment committee of Brandes Small Cap Value Fund purchased shares of Prestige Consumer Healthcare Inc., along with Globant and Sonoco Products Company during the third quarter [3]

Core Insights - OraSure Technologies reported a quarterly loss of $0.13 per share, which was better than the Zacks Consensus Estimate of a loss of $0.16, representing an earnings surprise of +18.75% [1] - The company posted revenues of $27.09 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 7.05% and down from $39.92 million year-over-year [2] - OraSure shares have declined approximately 28.8% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - Over the last four quarters, OraSure has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $31.22 million, and for the current fiscal year, it is -$0.67 on revenues of $121.53 million [7] Market Outlook - The company's stock is currently rated Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical - Products industry, to which OraSure belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8]